Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation
Authors:
Open Access
- 1 July 2022
- journal article
- research article
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21 (4) , 630-636
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- The chemical evolution of oligonucleotide therapies of clinical utilityNature Biotechnology, 2017
- Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutationJournal of Cystic Fibrosis, 2017
- The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domainBiochemical Pharmacology, 2016
- From the endoplasmic reticulum to the plasma membrane: mechanisms of CFTR folding and traffickingCellular and Molecular Life Sciences, 2016
- Facilitating Structure-Function Studies of CFTR Modulator Sites with Efficiencies in Mutagenesis and Functional ScreeningSLAS Discovery, 2015
- RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic PlatformAnnual Review of Pharmacology and Toxicology, 2010
- Domain Interdependence in the Biosynthetic Assembly of CFTRJournal of Molecular Biology, 2007
- Processing of CFTR: Traversing the cellular maze—How much CFTR needs to go through to avoid cystic fibrosis?Pediatric Pulmonology, 2005
- The ΔF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTRNature Structural & Molecular Biology, 2004
- Nonsense-mediated mRNA decayin health and diseaseHuman Molecular Genetics, 1999